|
New approaches for MCL
Mantle Cell Lymphoma medical abstracts
Durable responses
with the antiangiogenic metronomic regimen RT-PEPC in elderly patients with
recurrent mantle cell lymphoma (MCL).
Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose
Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL
Autologous vs Allogeneic Cell Transplantation for Mantle Cell Lymphoma (MCL):
Outcomes over a 10-Year Period at City of Hope
Outcomes of Autologous and Allogeneic BMT for Mantle Cell Lymphoma
High-dose
chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle
cell lymphoma
Allogeneic Hematopoietic Cell Transplantation after Fludarabine and 2 Gy Total
Body Irradiation for Relapsed and Refractory Mantle Cell Lymphoma.
Antitumor activity of rituximab plus thalidomide in patients with
relapsed/refractory mantle cell lymphoma
Early Consolidation with Myeloablative Radiochemotherapy Followed by Autologous
Stem Cell Transplantation in First Remission Significantly Prolongs
Progression-Free Survival in Mantle Cell Lymphoma
Rituximab/Chemotherapy Induction Treatment Followed by High-Dose Therapy and
Autologous Transplantation in Patients with Mantle Cell Lymphoma
Rituximab and Stem Cell Transplantation Produces Durable Remissions in Mantle
Cell Lymphoma
Eradication of Minimal Residual Disease during Treatment of Mantle Cell Lymphoma
A Phase II Study of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) for
Treatment of Patients with Relapsed and Refractory Mantle Cell Lymphoma (MCL)
Phase II Trial of Bortezomib in Mantle Cell Lymphoma
Early
consolidation by myeloablative radiochemotherapy followed by autologous stem
cell transplantation in first remission significantly prolongs progression-free
survival in mantle-cell lymphoma: results of a prospective randomized trial of
the European MCL Network
| 
